Background. The reliability of kidney biopsy as the sole means for assessing kidneys from extended-criteria donors (ECDs) to be allocated to single or dual transplantation is still a matter of debate. Methods. We compared retrospectively 3 years graft survival and renal function in 44 recipients of a single kidney graft from a marginal donor with good renal function and a Karpinski histological score of ≤3 and 56 recipients of a single transplant with a Karpinski score of 4 or 5. The donors' and recipients' characteristics were compared by means of Wilcoxon's rank-sum test and Fisher's exact test, and survival was analysed using the log-rank test and Cox regression survival analysis.
A B S T R AC T
Background. The reliability of kidney biopsy as the sole means for assessing kidneys from extended-criteria donors (ECDs) to be allocated to single or dual transplantation is still a matter of debate. Methods. We compared retrospectively 3 years graft survival and renal function in 44 recipients of a single kidney graft from a marginal donor with good renal function and a Karpinski histological score of ≤3 and 56 recipients of a single transplant with a Karpinski score of 4 or 5. The donors' and recipients' characteristics were compared by means of Wilcoxon's rank-sum test and Fisher's exact test, and survival was analysed using the log-rank test and Cox regression survival analysis.
Results. The donors with the worse histological scores were slightly younger (68.0 ± 4.74 versus 71.3 ± 4.6 years, P < 0.01) and had a higher glomerular filtration rate (85.8 ± 28.2 versus 76.3 ± 26.53 mL/min, P = 0.013), but there was no difference in serum creatinine levels (0.83 ± 0.24 versus 0.85 ± 0.30 mg/ dL, P = 0.381). Three years after transplantation, there was no difference between the two groups in terms of recipient serum creatinine levels (1.94 ± 0.69 versus 1.74 ± 0.49 mg/dL, P = 0.134), estimated glomerular filtration rate (eGFR, 45.6 ± 21.1 versus 51.7 ± 22.0 mL/min, P = 0.331) or the rates of graft loss (27.3 versus 35.7%, P = 0.47), delayed graft function or acute rejection. Conclusions. In our experience, provided the donor has a normal renal function, a difference in the pre-transplant histological score of kidneys from marginal cadaveric donors do not have a significant influence on the outcome 3 years after transplantation. Our findings might represent a basis for designing a randomized controlled trial of using a higher histological score threshold for the DKT allocation of grafts from ECDs with a normal renal function.
I N T R O D U C T I O N
Renal transplantation is considered the best treatment for endstage renal disease (ESRD) [1, 2] , but the number of transplantations performed every year is not sufficient to reduce the number of patients on the waiting list [3] . Various strategies have been developed in an attempt to address this problem, including the use of extended-criteria donors (ECDs), dual kidney transplantation (DKT) and donation after circulatory death [4, 5] .
The criteria used to decide whether kidneys from marginal donors are suitable for single kidney transplantation (SKT) or DKT are not univocal. Useful parameters to consider when making this decision are the history of the donor, his/her renal function, the anatomical appearance of the kidneys at ultrasonography and macroscopic evaluation and the histological findings of the pre-implantation biopsy [6] . Some authors place a great emphasis on donor renal function at the time of retrieval [7, 8] , whereas others consider the severity of the renal lesions as classified by particular scoring systems (e.g. Karpinski histological score) [9] as a good predictor of future graft outcome [10] [11] [12] [13] [14] . The latter strategy was adopted by many centres in Italy after the publication of two studies by the group of Remuzzi [15, 16] , showing that graft outcomes of SKT harvested from standard donors are comparable with those of SKT harvested from ECDs with a Karpinski score of ≤3 or, in the case of DKT, a Karpinski score of >3. In view of these extremely positive results, the number of DKTs performed in Italy each year has increased from 3.98 to 7.33% of all cadaveric kidney grafts over the last decade (data available on the Italian National Transplantation Centre website https://trapianti.sanita.it/statistiche/).
However, although this strategy has allowed the retrieval of kidneys from very old donors that otherwise would have been discarded, doubts still exist concerning the degree of histological damage that is acceptable for SKT. In the graft allocation system of our region, kidneys with a Karpinski score of four or five may be allocated for SKT if the donor's estimated glomerular filtration rate (eGFR) is at least 60 mL/min. In our view, this has the benefit of increasing the number of transplantations without adversely affecting graft outcomes.
The aim of this study was to compare graft survival and graft renal function 3 years after SKT in patients receiving a kidney from an ECD with good renal function and a Karpinski score of 4 or 5 and in patients receiving a kidney from an ECD with a similar renal function but a Karpinski score of ≤3.
M E T H O D S

Patients
For this retrospective single-centre study, we selected consecutively from our cohort of transplanted patients those who had received a single renal graft between 2005 and 2010 from a cadaveric donor aged >60 years with an eGFR of >55 mL/min (calculated by means of the Cockroft-Gault formula using the first serum creatinine available during the hospital stay of the donor) [17] that underwent histological evaluation at the time of organ retrieval. The patients were divided into two groups: those who received a transplant from a donor with a Karpinski histological score [9] of ≤3 (Group A) and those who received a transplant from a donor with a Karpinski score of 4 or 5 (Group B). The differences between the two groups were analysed in terms of donor characteristics at the time of transplantation (age, gender, serum creatinine levels, eGFR, kidney longitudinal dimension as measured by means of ultrasonography and cold ischaemia time). The recipients' characteristics were compared in terms of age at transplantation, gender, the incidence of delayed graft function (i.e. the need for dialysis during the first week after transplantation), the number of HLA mismatches and biopsy-proven acute rejections, serum creatinine levels, eGFR and the rate of graft loss after 3 years of transplantation.
Immunosuppressive regimen
All of the patients received induction therapy with basiliximab 20 mg (Simulect, Novartis Pharma, Basel and Switzerland) on post-transplantation days 0 and 4; methylprednisolone i.v. on Days 0-4, followed by oral methylprednisolone in accordance with our institutional protocol; cyclosporine (Sandimmun Neoral, Novartis Pharma); and mycophenolic acid (Myfortic, Novartis Pharma) or everolimus (Certican, Novartis Pharma) ( Table 1 ).
The patients were followed up in our outpatient clinic in accordance with our centre protocol.
Histological analysis and allocation protocol
Pre-implantation specimens were wedge biopsied by the surgeon at the time of organ retrieval. The specimens were stained with haematoxylin eosin, PAS and Masson's Trichrome, and the histological evaluation was made by the Pathology Unit of our institution using Karpinski's histological score [9] (Table 2) .
Once the score was obtained, the kidneys were allocated according to the protocol shown in Table 3 .
Statistical analysis
The continuous variables are expressed as mean values and standard deviations, or median values and quartiles when they were not normally distributed according to the Shapiro-Wilk test; the comparisons were made using Student's t test for independent samples or Wilcoxon's rank-sum test as appropriate. The non-continuous variables were compared using the χ 2 test or Fisher's exact test as appropriate. Death-uncensored graft survival and patient survival are expressed using KaplanMeier curves; the differences between the survival curves were assessed by means of the log-rank test. Cox regression survival analysis was used to assess the influence of the baseline covariates on 3 years graft survival. All of the tests were made using SPSS software.
R E S U LT S
We used our database of renal transplant patients to select 100 patients who received a kidney from an ECD: 44 received a kidney with a Karpinski score of ≤3 (Group A) and 56 received a kidney with a Karpinski score of 4 or 5 (Group B).
Donor characteristics
The characteristics of the donors in the two groups were similar in terms of serum creatinine levels (0.87 ± 0.27 versus 0.83 ± 0.24 mg/dL, P = 0.381), gender, the ultrasonographic longitudinal measurement of the transplanted kidney (107 ± 9.4 versus 108 ± 8.0 mm, P = 0.893) and cold ischaemia time (18.0 ± 7.2 versus 19.6 ± 6.5 h, P = 0.17). The donors in Group B had a higher eGFR (76.3 ± 26.53 versus 85.8 ± 28.2 mL/min; P = 0.013), and were slightly younger than those in Group A (71.3 ± 4.6 versus 68.0 ± 4.74 years; P < 0.01). The cause of death of the donors was mainly cardiovascular (86.4% in Group A and 71.4% in Group B). Thirty-one percent of the donors in Group A were hypertensive, as against 50% in Group B (not significant). There was no diabetic donor (Table 4) .
Baseline characteristics and result of the recipients
The baseline characteristics of the recipients are shown in Table 5 . There was no between-group difference in terms of age, gender or the number of mismatches. All of the recipients were Caucasians, except for two Asian patients. Two recipients in each group were undergoing second transplants. 
O R I G I N A L A R T I C L E
S h o u l d w e r e c o n s i d e r p r e -t r a n s p l a n t h i s t o l o g i c a l s c o r e ?
Renal function 3 years after transplantation was not different between the two groups in terms of serum creatinine levels (1.94 ± 0.69 versus 1.74 ± 0.49 mg/dL, P = 0.134) or eGFR (45.6 ± 21.1 versus 51.7 ± 22.0 mL/min, P = 0.331). The rates of graft loss uncensored for death were similar (27.3 versus 32.1%, P = 0.47). Death with a functional graft occurred in eight cases in Group A and 10 in Group B (P = 0.967): the cause of death was related to infectious complications in all cases, except for three cases in Group A (two cardiovascular and one neoplastic) and two in Group B (one cardiovascular and one secondary to a surgical complication). Graft loss and dialysis resumption occurred in four patients in Group A and eight in Group B (P = 0.52); in each group, these were two cases due to acute rejection and two cases related to surgical complications plus four graft losses due to chronic rejection occurred in Group B.
Survival analysis
In Figures 1 and 2 are shown, respectively, the KaplanMeier curves of death-censored graft survival and patient survival. The log-rank analyses of both curves did not reveal any statistically significant difference in 3-years graft survival (P = 0.45) or patient survival (P = 0.9) between the two groups.
In the multivariate analysis, recipient age at transplantation and the occurrence of DGF had a significant influence on 3 years graft survival (Table 6 ).
Other parameters
The other parameters that we evaluated that might have had an influence on graft survival or renal function resulted similar between the two groups. In particular, we observed seven acute cellular rejections (one case 2a, three cases 1a and one case 1b according to the Banff classification [18] . Two patients were treated with corticosteroids but did not undergo a kidney biopsy) and one humoral-mediated rejection in Group A and eight cellular rejections in Group B (one case 2a, three cases 1a, the others not biopsy proven). The rate of delayed graft function was comparable in the two groups (56 versus 39%; P = 0.06).
D I S C U S S I O N
We found no differences in 3 years graft survival or renal function between patients undergoing SKT with a kidney from an ECD with good renal function and a Karpinski score of ≤3 and those undergoing SKT with a kidney from an ECD with a similar renal function but a Karpinski score of 4 or 5. On the basis of these findings, it could be concluded that allocating organs such as those of our Group B to SKT might make it possible to reduce the number of patients on the waiting list in comparison with allocating kidneys only on the basis of preimplantation biopsy score.
It is difficult to find comparable studies in the literature, but there are some published data that seem to be indirectly in line with our conclusions. Cruzado et al. [19] demonstrated that DKT recipients who lost one of the two kidneys (mainly because of thrombosis) had 5-and 10-year graft survival rates similar to those receiving a DKT with two functioning kidneys, albeit with a lower eGFR. 
O R I G I N A L A R T I C L E
S h o u l d w e r e c o n s i d e r p r e -t r a n s p l a n t h i s t o l o g i c a l s c o r e ? Donor age and donor eGFR were slightly but statistically different between our two groups insofar as the donors with the worse histological scores were younger and had better renal function. This is an important point that merits comment. First of all, it might be said that the two groups were not perfectly comparable because Group B donors had slightly better baseline characteristics, although the differences between the two groups were small (about 3 years of age and 9 mL/min of eGFR), and we do not consider this as a significant bias of this study since the donor eGFR and donor age did not have any impact on graft survival when assessing the covariate influence on survival analysis by Cox regression. Second, this difference in donors' characteristics allows us to emphasize the main message of this study, namely the fact that if we want to allocate safely to SKT kidneys with a score of 4 or 5, we must be particularly careful in selecting only those kidneys with a preserved renal function.
Furthermore, there are concerns about the use of the preimplantation biopsy. A donor's histological score does not correlate perfectly with renal function, and there are some doubts about the reliability of histological scores because a renal biopsy is by definition focal and usually performed on the sub-capsular region. In addition, it has been argued that the Karpinski score is an operator-dependent, poorly reproducible procedure whose value should be reduced or at least not overestimated for clinical or scientific purpose. In a small study, Murve et al. [20] took kidneys that had been refused by United Network for Organ Sharing centres on the basis of biopsy findings and compared the results of a detailed histological examination with those of the wedge biopsy at the time of retrieval, finding that the latter may overestimate the percentage of glomerulosclerosis. On the other hand, Mazzucco et al. [21] instead found that wedge and fine needle biopsy findings provide reliable data concerning the actual kidney status, especially if the size of the biopsy is sufficient and there are more than 10 glomeruli.
The 3-year graft and patient survival in our study was, respectively, around 70 and 80% in both groups. These outcomes are in line with data of grafts from ECD derived from larger clinical trials and registers. ( [22] and reviewed in [5] ).
Our study has the limitations of being retrospective, singlecentre and with a small patient population. Furthermore, biopsies were not re-evaluated retrospectively by a single pathologist in order to reduce the interoperator variability. Nevertheless, all of the transplantations were performed within a period of 5 years, and a 3-year follow-up may be a sufficient time to reveal the effect of a reduced number of functioning nephrons in the group with the worse histological score and to anticipate long-term graft survival.
This hypothesis is also supported by the better results of the study of Lucarelli et al. [23] , which even found that 5-year graft survival was better for DKT than SKT of ECD kidneys allocated on the basis of their Karpinski score. The immunosuppressive therapy deserves a further comment. Given that a slightly higher percentage of patients in the group with the worst score were treated with everolimus, one might argue that the difference in GFR in favour of this group may be due to a reduced exposure to the calcineurin inhibitor. In our opinion, this observation is unfounded, because the difference in the proportion of patients treated with mTOR-inhibitors (mTOR-i) in the two groups is very small (20% in the first and 33% in the second) and occurred by chance because we do not adopt a policy of treating patients transplanted with organs from ECD with everolimus or sirolimus. Finally, from the data of the literature [24] [25] [26] the mean difference of eGFR between patients treated with standard doses of cyclosporine plus mycophenolic acid versus everolimus plus low dose of cyclosporine is ∼10 mL/min, which is more or less the difference of GFR that we found between our two groups. Given that only 13% more 
of the patients in Group B was treated with mTOR-i, the difference in GFR cannot be attributed only to the lower exposure to cyclosporine. However, despite these limitations, we feel that our findings justify our policy of allocating organs: between 2005 and 2010, we increased the number of ECD transplantations by 23%, and the total number of transplants at our centre by 9%, without any adverse effect on transplant outcomes. Our findings might represent a basis for designing a randomized controlled trial of using a higher histological threshold for the DKT allocation of grafts from ECDs with a normal renal function.
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